Oncternal Therapeutics (ONCT)
(Real Time Quote from BATS)
$1.53 USD
0.00 (0.00%)
Updated Sep 23, 2024 09:40 AM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Oncternal Therapeutics (ONCT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$10.00 | $18.00 | $2.00 | 553.59% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Oncternal Therapeutics comes to $10.00. The forecasts range from a low of $2.00 to a high of $18.00. The average price target represents an increase of 553.59% from the last closing price of $1.53.
Analyst Price Targets (2 )
Broker Rating
Oncternal Therapeutics currently has an average brokerage recommendation (ABR) of 2.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, one is Strong Buy, representing 33.33% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.33 | 2.33 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/12/2024 | Brookline Capital Markets | Kemp Dolliver | Strong Buy | Hold |
9/12/2024 | Northland Capital Markets | Carl Byrnes | Strong Buy | Hold |
7/16/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.33 |
ABR (Last week) | 2.33 |
# of Recs in ABR | 3 |
Average Target Price | $10.00 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | -2.92 |
ONCT FAQs
Oncternal Therapeutics, Inc. (ONCT) currently has an average brokerage recommendation (ABR) of 2.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 3 brokerage firms.
The average price target for Oncternal Therapeutics, Inc. (ONCT) is $10.00. The current on short-term price targets is based on 2 reports.
The forecasts for Oncternal Therapeutics, Inc. (ONCT) range from a low of $2 to a high of $18. The average price target represents a increase of $553.59 from the last closing price of $1.53.
The current UPSIDE for Oncternal Therapeutics, Inc. (ONCT) is 553.59%
Based on short-term price targets offered by two analysts, the average price target for Oncternal Therapeutics comes to $10.00. The forecasts range from a low of $2.00 to a high of $18.00. The average price target represents an increase of 553.59% from the last closing price of $1.53.